Evidence map›Paper›PMID 32321802›Full record

ArticleJournal of virology2020

Defective Influenza A Virus RNA Products Mediate MAVS-Dependent Upregulation of Human Leukocyte Antigen Class I Proteins.

Mir Munir A Rahim, Brendon D Parsons, Emma L Price, Patrick D Slaine, Becca L Chilvers, Gregory S Seaton, Andrew Wight, Daniel Medina-Luna, Sayanti Dey, Shannen L Grandy and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Mir Munir A Rahim *Department of Biomedical Sciences, University of Windsor, Windsor, Ontario, Canada.
Brendon D Parsons *Department of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.ORCID 0000-0002-9255-0290
Emma L PriceDepartment of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
Patrick D SlaineDepartment of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
Becca L ChilversDepartment of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
Gregory S SeatonDepartment of Biochemistry and Molecular Biology, Dalhousie University, Halifax, Nova Scotia, Canada.
Andrew WightDepartment of Cancer Immunology and Virology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
Daniel Medina-LunaDepartment of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
Sayanti DeyDepartment of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
Shannen L GrandyDepartment of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
Lauryn E AndersonDepartment of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
Natalia Zamorano CuervoCentre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Quebec, Canada.
Nathalie GrandvauxCentre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Quebec, Canada.
Marta M GagliaDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, USA.ORCID 0000-0002-1791-0663
Alyson A KelvinDepartment of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
Denys A Khaperskyy *Department of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
Craig McCormick *Department of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada craig.mccormick@dal.ca andrew.makrigiannis@dal.ca.ORCID 0000-0003-2794-3722
Andrew P Makrigiannis *Department of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada craig.mccormick@dal.ca andrew.makrigiannis@dal.ca.
Dalhousie University · CACentre Hospitalier de l’Université de Montréal · CADana-Farber Cancer Institute · USTufts University · USUniversity of Windsor · CA

Funding

Molecular Mechanism of Action of the Influenza PA-X Host Shutoff ProteinR01AI137358 · NIAID · TUFTS UNIVERSITY BOSTON · PI GAGLIA, MARTA MARIA · 2018 to 2022
$2.0M
CIHR MOP-130527CIHR MOP-136817CIHR MOP-155906NIAID NIH HHS R01 AI137358
6 · The paper itself

Abstract

Influenza A virus (IAV) increases the presentation of class I human leukocyte antigen (HLA) proteins that limit antiviral responses mediated by natural killer (NK) cells, but molecular mechanisms for these processes have not yet been fully elucidated. We observed that infection with A/Fort Monmouth/1/1947(H1N1) IAV significantly increased the presentation of HLA-B, -C, and -E on lung epithelial cells. Virus entry was not sufficient to induce HLA upregulation because UV-inactivated virus had no effect. Aberrant internally deleted viral RNAs (vRNAs) known as mini viral RNAs (mvRNAs) and defective interfering RNAs (DI RNAs) expressed from an IAV minireplicon were sufficient for inducing HLA upregulation. These defective RNAs bind to retinoic acid-inducible gene I (RIG-I) and initiate mitochondrial antiviral signaling (MAVS) protein-dependent antiviral interferon (IFN) responses. Indeed, MAVS was required for HLA upregulation in response to IAV infection or ectopic mvRNA/DI RNA expression. The effect was partially due to paracrine signaling, as we observed that IAV infection or mvRNA/DI RNA-expression stimulated production of IFN-β and IFN-λ1 and conditioned media from these cells elicited a modest increase in HLA surface levels in naive epithelial cells. HLA upregulation in response to aberrant viral RNAs could be prevented by the Janus kinase (JAK) inhibitor ruxolitinib. While HLA upregulation would seem to be advantageous to the virus, it is kept in check by the viral nonstructural 1 (NS1) protein; we determined that NS1 limits cell-intrinsic and paracrine mechanisms of HLA upregulation. Taken together, our findings indicate that aberrant IAV RNAs stimulate HLA presentation, which may aid viral evasion of innate immunity.

Indexed as

A549 CellsAdaptor Proteins, Signal TransducingDatabases, GeneticDEAD Box Protein 58Epithelial CellsGenes, MHC Class IHLA AntigensHost-Pathogen InteractionsHumansImmunity, InnateInfluenza A virusInfluenza A Virus, H1N1 SubtypeInfluenza, HumanKiller Cells, NaturalLungRNA, ViralAdaptor Proteins, Signal TransducingDEAD Box Protein 58HLA AntigensMAVS protein, humanRNA, ViralViral Nonstructural Proteinsclass I HLAclass I MHCDI RNAsinfluenza A virusinterferonKIRMAVSmvRNAsNK cellsRIG-I

Identifiers

PMID32321802
PMCPMC7307169
OpenAlexW3018023330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.